Measuring Clinical Trial Transparency: An Empirical Analysis of Newly Approved Drugs and Large Pharmaceutical Companies

BMJ Open - United Kingdom
doi 10.1136/bmjopen-2017-017917
Full Text
Abstract

Available in full text

Categories
Medicine
Date
Authors
Publisher

BMJ

Related search

Budget Impact of Newly Approved Drugs by the Sicilian Drug Formulary Committee: An Introductive Analysis

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

Three Newly Approved Drugs for Chronic Lymphocytic Leukemia: Incorporating Ibrutinib, Idelalisib, and Obinutuzumab Into Clinical Practice

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2015English

Budget Transparency in Local Governments: An Empirical Analysis

SSRN Electronic Journal
2011English

Economic and Non-Economic Determinants of Iranian Pharmaceutical Companies’ Financial Performance: An Empirical Study

BMC Health Services Research
Health Policy
2019English

Buyouts of Indian Pharmaceutical Companies by Multinational Pharmaceutical Companies: An Issue of Concern

Journal of Young Pharmacists
ToxicologyPharmaceuticsPharmacology
2011English

Style and Organizational Performance of Nigerian Companies: An Empirical Analysis

Journal of Applied Sciences
2008English

Clinical Trial Transparency Update: An Assessment of the Disclosure of Results of Company-Sponsored Trials Associated With New Medicines Approved in Europe in 2012

Current Medical Research and Opinion
Medicine
2015English

The Effect of Internal Corporate Social Responsibility on Job Satisfaction: An Empirical Study on Jordanian Pharmaceutical Companies

Journal of Business & Management (COES&RJ-JBM)
2020English

An Empirical Analysis of M a a Performance of Chinese Listed Companies

2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy